Close Menu

NEW YORK (GenomeWeb) – NeoGenomics announced today its participation as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice, or NCI-MATCH, precision medicine cancer treatment clinical trial.

As a designated sequencing lab for the trial, the Fort Myers, Florida-based company will use its NeoType Discovery Panel to identify patients who may be eligible for treatment of their tumor types at clinical sites participating in NCI-MATCH. The panel assesses 320 cancer-related genes in solid tumors, hematologic malignancies, and advanced sarcomas.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.